公开(公告)号：US12123005B2

公开(公告)日：2024-10-22

申请号：US16508021

申请日：2019-07-10

申请人： The Trustees of Columbia University in the City of New York

发明人： Antonio Iavarone ,  Anna Lasorella ,  Raul Rabadan

IPC分类号： C12Q1/6886 ,  C07K14/47 ,  C07K14/71 ,  C07K14/82 ,  C07K16/18 ,  C07K16/28 ,  C12N9/12 ,  C12N15/62 ,  G01N33/574

CPC分类号： C12N15/62 ,  C07K14/47 ,  C07K14/71 ,  C07K14/82 ,  C07K16/18 ,  C07K16/2863 ,  C12N9/12 ,  C12Q1/6886 ,  G01N33/57492 ,  C07K2319/00 ,  C07K2319/73 ,  C12Q2600/158 ,  G01N2333/91205

摘要： The invention discloses oncogenic fusion proteins. The invention provides methods for treating gene-fusion based cancers.

公开(公告)号：US20230365690A1

公开(公告)日：2023-11-16

申请号：US18040888

申请日：2021-08-08

申请人： NORTHWESTERN UNIVERSITY ,  THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK

发明人： Víctor Andrés Arrieta González ,  Raul Rabadan ,  Fabio M. Iwamoto ,  Adam M. Sonabend Worthalter

IPC分类号： C07K16/28 ,  A61P35/04 ,  A61K45/06 ,  G01N33/574

CPC分类号： C07K16/2818 ,  A61P35/04 ,  A61K45/06 ,  G01N33/57484 ,  G01N2440/14 ,  G01N2333/91205

摘要： Disclosed herein are methods for identifying subjects, diagnosed as having glioblastoma (GBM), as likely responders to treatment with a programmed death protein 1 (PD-1) blockade. In some embodiments, the subjects are identified by determining the level of phosphorylated extracellular-signal-regulated kinase (p-ERK) in a GBM tumor sample from the subject. In some embodiments, the GBM is recurrent. Also disclosed herein are methods of treating GBM subjects, whereby the methods include (1) identifying the subject as a likely responder to PD-1 blockade, and (2) administering a PD-1 inhibitor and/or a programmed death-ligand 1 (PD-L1) inhibitor.

公开(公告)号：US20230333121A1

公开(公告)日：2023-10-19

申请号：US18308318

申请日：2023-04-27

申请人： ANACALYPSIS THERAPEUTICS, IKE

发明人： Hardy J. RIDEOUT

IPC分类号： G01N33/68

CPC分类号： G01N33/6896 ,  G01N2333/91205 ,  G01N2440/14 ,  G01N2800/50 ,  G01N2800/2835 ,  G01N2800/52 ,  G01N2800/56

摘要： Provided herein are methods for making a clinical decision in an individual having or suspected of having a neurodegenerative disease or disorder by determining a level, post-translational modification, or both of a plurality of biomarkers.

公开(公告)号：US20190183879A1

公开(公告)日：2019-06-20

申请号：US16282716

申请日：2019-02-22

申请人： Arog Pharmaceuticals, Inc.

发明人： Vinay K. Jain

IPC分类号： A61K31/4709 ,  G01N33/574 ,  A61K45/06 ,  A61K9/00

CPC分类号： A61K31/4709 ,  A61K9/0053 ,  A61K45/06 ,  C12Y207/10001 ,  G01N33/57426 ,  G01N2333/91205 ,  A61K2300/00

摘要： The present invention relates to the use of crenolanib, in a pharmaceutically acceptable salt form for the treatment of FLT3 mutated proliferative disorders driven by constitutively activated mutant FLT3, and to a method of treatment of warm-blooded animals, preferably humans, in which a therapeutically effective dose of crenolanib is administered to an animal suffering from said disease or condition:

公开(公告)号：US10054589B2

公开(公告)日：2018-08-21

申请号：US14767434

申请日：2014-02-12

申请人： NATIONAL JEWISH HEALTH

发明人： Donald Y. M. Leung ,  Elena Goleva ,  Lingbo Li

IPC分类号： C12Q1/48 ,  G01N33/573 ,  C07K16/40 ,  C12N15/113

CPC分类号： G01N33/573 ,  C07K16/40 ,  C07K2317/76 ,  C12N15/1137 ,  C12N2310/14 ,  C12N2320/30 ,  C12Q1/485 ,  G01N2333/91205 ,  G01N2333/91215 ,  G01N2800/122 ,  G01N2800/52 ,  G01N2800/7095

摘要： The present invention is directed toward novel methods to identify as well as to treat a subject having an inflammatory disease resistant to corticosteroids.

公开(公告)号：US20180066068A9

公开(公告)日：2018-03-08

申请号：US15305340

申请日：2015-04-21

申请人： Millennium Pharmaceuticals, Inc.

发明人： Rachael L. BRAKE ,  Anne L. BURKHARDT ,  Helen D. HE MCDOUGALL ,  Karuppiah KANNAN ,  Matthew THEISEN ,  Stephen M. TIRRELL

IPC分类号： C07K16/40 ,  A61K31/437 ,  G01N33/573 ,  G01N33/574

CPC分类号： C07K16/40 ,  A61K31/437 ,  C07K2317/20 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92 ,  G01N33/573 ,  G01N33/574 ,  G01N2333/91205 ,  G01N2800/52 ,  G01N2800/56

摘要： The invention relates to antibody molecules which bind pSYK, and methods for using the same for diagnosis, prognosis, to select patients for treatment with a SYK-targeted therapy, or evaluate the pharmacodynamic profile of a SYK-targeted therapy.

公开(公告)号：US09903867B2

公开(公告)日：2018-02-27

申请号：US14985190

申请日：2015-12-30

申请人： NESTEC S.A.

发明人： Phillip Kim ,  Anjali Jain ,  Sharat Singh

IPC分类号： G01N33/574 ,  A61K39/00

CPC分类号： G01N33/57419 ,  A61K39/00 ,  A61K2039/505 ,  G01N33/57492 ,  G01N2333/70596 ,  G01N2333/912 ,  G01N2333/91205 ,  G01N2333/91215 ,  G01N2440/14 ,  G01N2800/52 ,  G01N2800/54

摘要： The present invention provides assays and methods for predicting the survival of a subject having colorectal cancer (CRC), thereby determining whether the subject will have a good prognosis or poor prognosis. The present invention also provides assays and methods for predicting therapeutic efficacy and/or response to anti-cancer therapeutics in a subject having CRC, thereby selecting a therapeutic regimen to which the subject is likely to be responsive.

公开(公告)号：US09880169B2

公开(公告)日：2018-01-30

申请号：US15011003

申请日：2016-01-29

申请人： Levi A. Garraway ,  Caroline Emery ,  Nikhil Wagle

发明人： Levi A. Garraway ,  Caroline Emery ,  Nikhil Wagle

IPC分类号： G01N33/573 ,  G01N33/574 ,  C12N9/12 ,  C12Q1/68

CPC分类号： G01N33/5743 ,  C12N9/1205 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/136 ,  C12Q2600/156 ,  C12Y207/12002 ,  G01N2333/91205 ,  G01N2500/10 ,  G01N2500/20

摘要： Nucleic acids and proteins having a mutant MEK sequence, and methods concerning identification of patients having resistance to treatment with anti-cancer agents, specifically inhibitors of RAF or MEK are provided. Methods of treatment and for optimizing treatment for patients having a mutation in a MEK1 sequence are also provided.

公开(公告)号：US20180011103A1

公开(公告)日：2018-01-11

申请号：US15661241

申请日：2017-07-27

申请人： Janssen Diagnostics, LLC ,  Pfizer Inc.

发明人： Antonio GUALBERTO ,  Maria Luisa PACCAGNELLA ,  Carrie L. MELVIN ,  Madeline I. REPOLLET ,  David CHIANESE ,  Mark Carle CONNELLY ,  Leonardus Wendelinus Mathias Marie TERSTAPPEN

IPC分类号： G01N33/574 ,  G01N33/50 ,  G01N30/02

CPC分类号： G01N33/57496 ,  G01N30/02 ,  G01N33/5023 ,  G01N33/5064 ,  G01N33/574 ,  G01N33/57492 ,  G01N2333/4742 ,  G01N2333/4745 ,  G01N2333/71 ,  G01N2333/91205 ,  G01N2458/00 ,  G01N2800/52 ,  B01D15/3804

摘要： Methods for the detection, enumeration and analysis of circulating tumor cells expressing insulin-like growth factor-1 receptors (IGF-1R) are disclosed. These methods are useful for cancer screening and staging, development of treatment regimens, and for monitoring for treatment responses, cancer recurrence or the like. Test kits that facilitate the detection, enumeration and analysis of such circulating tumor cells are also provided.

公开(公告)号：US20170370907A1

公开(公告)日：2017-12-28

申请号：US15613052

申请日：2017-06-02

申请人： ACEA Biosciences, Inc.

发明人： Yama A. Abassi ,  Naichen Yu ,  Josephine Atienza ,  Xiao Xu ,  Xiaobo Wang

IPC分类号： G01N33/50 ,  G01N33/543 ,  C12Q1/00 ,  G01N27/02

CPC分类号： G01N33/5041 ,  C12Q1/002 ,  G01N27/021 ,  G01N33/5014 ,  G01N33/5438 ,  G01N2333/4716 ,  G01N2333/705 ,  G01N2333/91205 ,  G01N2500/04 ,  G01N2500/10

摘要： A method of identifying a potential therapeutic compound that affects a Receptor Tyrosine Kinase (RTK) pathway in cancer cells, which includes: providing a device capable of measuring cell-substrate impedance; culturing cancer cells in serum-free media in at least two wells of the device; adding to a first well a proposed therapeutic compound that affects a RTK pathway and a RTK stimulating factor for the RTK pathway to form a test well, and adding to another well the RTK stimulating factor to form a control well; continuously monitoring cell-substrate impedance of the at least two wells and optionally determining cell indices from the monitored cell-substrate impedance; and determining a difference in impedance or optionally cell index between the test well and control well; and if significantly different, concluding the proposed therapeutic compound is therapeutically active in the RTK pathway within the cancer cells.